FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 782 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Adjuvant Treatment with Nivolumab Plus Ipilimumab Combination Fails to Improve DFS... February 22, 2023 Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t... October 15, 2021 Foodie Fridays: It’s Cucumber Season! July 23, 2021 Great Oaks Grow From Small Acorns Oncology Is Committed to Doing... September 9, 2022 Load more HOT NEWS A Cancer Revolution: What the experts think of the new Science... FDA Granted Accelerated Approval to Tazemetostat for Follicular Lymphoma Analysis Shows Women with High Breast Cancer Recurrence Scores Benefit from... Spending Review 2021: Promising commitments, but a lot of unanswered questions
